Richard H. Hughes, IV, Member of the Firm in the Health Care & Life Sciences practice, in the firm’s Washington, DC, office, was quoted in AIS Health, in “COVID Vaccine Prices Set to Rise After Commercialization — but Are They Fair?” by Peter Johnson. (Read the full version – subscription required.)
Following is an excerpt:
COVID-19 vaccines are likely to cost payers billions on an annual basis, according to a new analysis based on publicly disclosed vaccine price projections by executives from Pfizer Inc. and Moderna Inc. Despite criticism from some progressive members of Congress, who say the vaccines will be priced too high, one vaccine expert tells AIS Health, a division of MMIT, that per-dose costs aren’t out of line with typical vaccine prices for adults.
The federal government initially bought COVID vaccines, using its purchasing power to accelerate research and development. COVID vaccines were developed in record time, and federal purchasing helped manufacturers hit remarkable earnings figures. However, despite requests from the Biden administration for more funds to purchase future COVID vaccines, Congress seems unlikely to pay for more. Federal vaccination funds and vaccine stockpiles are likely to run out sometime in 2023. …
Richard Hughes IV, an attorney and partner at Epstein Becker Green — speaking about no specific vaccine or company — tells AIS Health that pricing a vaccine in the low-$100-per-dose range is not unusual.
“There was an analysis at the beginning of the vaccine rollout that estimated a vaccine would be cost-effective, if given to all adults, if it were priced up to $150. And these price points are within the range. If you look at all existing respiratory vaccines on the market, it’s within the price range,” Hughes says.
